Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05318599

Deep Learning Diagnostic and Risk-stratification for IPF and COPD

Deep Learning Diagnostic and Risk-stratification for Idiopathic Pulmonary Fibrosis and Chronic Obstructive Pulmonary Disease in Digital Lung Auscultations

Status
Recruiting
Phase
Study type
Observational
Enrollment
160 (estimated)
Sponsor
Pediatric Clinical Research Platform · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP), and chronic obstructive pulmonary disease (COPD) are severe, progressive, irreversibly incapacitating pulmonary disorders with modest response to therapeutic interventions and poor prognosis. Prompt and accurate diagnosis is important to enable patients to receive appropriate care at the earliest possible stage to delay disease progression and prolong survival. Artificial intelligence (AI)-assisted digital lung auscultation could constitute an alternative to conventional subjective operator-related auscultation to accurately and earlier diagnose these diseases. Moreover, lung ultrasound (LUS), a relevant gold standard for lung pathology, could also benefit from automation by deep learning.

Detailed description

Aim: To develop and determine the predictive power of an AI (deep learning) algorithm in identifying the acoustic and LUS signatures of IPF, NSIP and COPD in an adult population and discriminating them from age-matched, never smoker, control subjects with normal lung function. Methodology: A single-center, prospective, population-based case-control study that will be carried out in subjects with IPF, NSIP and COPD. A total of 120 consecutive patients aged ≥ 18 years and meeting IPF, NSIP or COPD international criteria, and 40 age-matched controls, will be recruited in a Swiss pulmonology outpatient clinic with a total of approximately 7000 specialized consultations per year, starting from August 2022. At inclusion, demographic and clinical data will be collected. Additionally, lung auscultation will be recorded with a digital stethoscope and LUS performed. A deep learning algorithm (DeepBreath) using various deep learning networks with aggregation strategies will be trained on these audio recordings and lung images to derive an automated prediction of diagnostic (i.e., positive vs negative) and risk stratification categories (mild to severe). Secondary outcomes will be to measures the association of analysed lung sounds with clinical, functional and radiological characteristics of IPF, NSIP and COPD diagnosis. Patients' quality of life will be measured with the standardized dedicated King's Brief Interstitial Lung Disease (K-BILD) and the COPD assessment test (CAT) questionnaires. Expected results: This study seeks to explore the synergistic value of several point-of-care-tests for the detection and differential diagnosis of ILD and COPD as well as estimate severity to better guide care management in adults

Conditions

Interventions

TypeNameDescription
DEVICELung auscultationDigital lung auscultation with the Eko core digital stethoscope (Eko Devices, Inc., CA, USA).
DEVICELung ultrasoundLung ultrasonography
OTHERQuality of Life's questionnairesImpact of the diseases on subjects' health-related quality of life measured with standardized questionnaires (K-BILD, CAT)
DIAGNOSTIC_TESTPulmonary functional testsSpirometry, body-plethysmographic parameters and lung diffusion capacity for carbon monoxide will be measured.

Timeline

Start date
2023-04-01
Primary completion
2024-10-06
Completion
2024-10-31
First posted
2022-04-08
Last updated
2024-04-12

Locations

1 site across 1 country: Switzerland

Source: ClinicalTrials.gov record NCT05318599. Inclusion in this directory is not an endorsement.